eVusheld Assessment reaL wORld effectiveness in the VA Health System - VALOR-VA
Study identifier:D8850R00014
ClinicalTrials.gov identifier:NCT05663957
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Observational Study to Assess the Real-World Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care in VA Health System in the United States
Medical condition
SARS-CoV-2, COVID-19
Phase
Phase 4
Healthy volunteers
No
Study drug
Evusheld
Sex
All
Actual Enrollment
5814
Study type
Observational
Age
12 Years - n/a
Date
Study Start Date: 04 Jan 2023
Primary Completion Date: 01 Sept 2023
Study Completion Date: 01 Sept 2023
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Mar 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
VA Informatics and Computing Infrastructure (VINCI)
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| EVUSHELD arm Individuals given EVUSHELD for prophylaxis | Drug: Evusheld EVUSHELD users |
| Concurrent Control arm Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD | - |
Contacts
Investigators
Principal Investigator
Scott L DuVall
VA Informatics and Computing Infrastructure (VINCI)
